Welcome to BioSeeker Group!

Analytical Tool - Angiogenesis in Oncology

Additional Information

Published Date Feb 21, 2012
Format PDF & Software Application
Publisher BioSeeker Group

Availability: In stock

€3,100.00

Quick Overview

The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents.
Request free sample pages from Analytical Tool - Angiogenesis in Oncology

"Analytical Tool - Angiogenesis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in anti-angiogenic drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:


The Package Includes

  • A progress analysis on current and emerging drugs
  • Information on most companies active in anti-angiogenic R&D in oncology
  • Information on key industry related anti-angiogenic drug projects in oncology
  • Data from most important clinical trials
  • Information on early developmental stage projects
  • Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

  • Tracking cutting edge companies, therapies and new technologies
  • Rapid identification of partners & competitors
  • Laying down a comprehensive framework for further analysis of the field
  • Producing presentations surrounding the development of anti-angiogenic drugs in oncology
  • Identifying emerging anti-angiogenic cancer products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of anti-angiogenic drug development in cancer, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.

Request free sample pages from Analytical Tool - Angiogenesis in Oncology

Other selected research from the 'Analytical Tool' category:


Analytical Tool - Peptides in Oncology
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer peptide R&D and business development. Learn More


Analytical Tool - Hematological Cancers
"Analytical Tool – Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. Learn More

Other selected research from the 'R&D' category:


Nucleic Acid Therapies in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 204 companies plus partners who are today developing 229 nucleic acid therapy drugs in 520 developmental projects in cancer across 173 different targets. In addition, there are 7 suspended drugs and another 177 drugs where development has been ceased. Learn More


Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2011-2021
do you want to discover the opportunities there? What are the commercial prospects for pharmaceutical anti-counterfeiting technology? Our new report shows you that industry and market’s revenue potential from... Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lymphoma, Melanoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the compound strategy of Antibodies. Learn More


Triple Analysis: Breast Cancer, Lung Cancer and Lymphoma
This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Lymphoma. Learn More

Other selected research from the 'Line of Treatment' category:


Pharmacovigilance Report and Analysis 2009: Present Challenges and Future Goals
Pharmacovigilance has been expanding in recent years, as companies are required to monitor drug safety post launch. Where is pharmacovigilance heading? What regulatory measures will continue, and which new processes will emerge? Learn More


Stem Cell Therapeutics Markets
Political and business events presage change for stem cell therapeutics, most notably the expected move by President Barack Obama to lift federal funding restrictions on stem-cell research. The U.S... Learn More